BiotechTube
Pheast Therapeutics

Pheast Therapeutics

Palo Alto, United States· Est.
pheast.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $76M

Overview

Pheast Therapeutics is a private, preclinical-stage biotech founded in 2020, focused on discovering and developing innate immune checkpoint inhibitors. Its core technology platform identifies novel 'don't eat me' signals, like CD24, to unleash macrophages against cancers resistant to existing immunotherapies. The company has initiated a Phase 1 trial for its lead anti-CD24 antibody, PHST001, and is backed by a $76M Series A round. Pheast aims to create next-generation therapies for patients with hard-to-treat solid tumors.

OncologyImmunology

Technology Platform

Proprietary platform to discover and validate novel 'don't eat me' signals (innate immune checkpoints) used by cancer cells to evade macrophage phagocytosis.

Funding History

1
Total raised:$76M
Seed$76M

Opportunities

Pheast targets a large unmet need in aggressive solid tumors (e.g., ovarian, TNBC) that are poorly served by existing T-cell immunotherapies.
Its platform for discovering novel macrophage checkpoints could yield multiple drug candidates, creating a pipeline in a nascent but promising field of innate immuno-oncology.

Risk Factors

The lead asset, PHST001, is in early-stage trials, facing significant clinical development risk where preclinical success may not translate to humans.
The company is highly dependent on this single program and will require substantial additional capital to advance its pipeline, subject to financing market conditions.

Competitive Landscape

Pheast competes in the emerging field of macrophage checkpoint inhibition. Key competitors include companies targeting the CD47-SIRPα axis (e.g., Gilead/Forty Seven, ALX Oncology). Pheast differentiates by focusing on the novel CD24 target, which may offer a better safety profile and efficacy in different tumor types compared to first-generation macrophage checkpoints.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →